[ad_1]
The government has concluded a vaccine contract with AstraZeneca, a vaccine developer for COVID-19.
A health official said: “We recently signed a vaccine supply contract with AstraZeneca, and we plan to announce the overall status of the contract and the amount insured next week when negotiations with individual vaccine developers conclude soon.”
The AstraZeneca vaccine requires two doses and, as a result of the initial data analysis of the phase 3 clinical trial, the preventive effect of the vaccine was 70-90%, depending on the method of administration.
The company previously promised a one-time dose of around $ 4.
The government has been negotiating purchase contracts for 5 corona vaccine products19 that entered phase 3 clinical trials.
AstraZeneca, known to have signed a contract for the first time, is reported to have been negotiating with Pfizer, Johnson & Johnson, Modena and Nova Bax, who approved emergency use in the UK on Day 2.
Pfizer and Moderna report that the vaccines they are developing are 95% and 94.1% effective, respectively.
The price is $ 19.5 for Pfizer and $ 15 to $ 25 for Modena per dose.
The AstraZeneca vaccine is somewhat less effective in prevention, but has the advantage of being cheap and can be distributed at 2-8 degrees compared to Pfizer, which must be distributed through a “cold chain” at a cryogenic temperature below – 70 ℃.
Additionally, you have the advantage that domestic manufacturing is possible by signing a vaccine shipment production contract with SK Bioscience in July.
Health and Welfare Minister Park Neung-hoo recently said: “We are looking for considerably more contracts than 30 million people, which is 60% of the total population.”
In next year’s budget, 900 billion won has been allocated to purchase vaccines to increase the number of vaccination targets to 44 million.
※ ‘Your report becomes news’ YTN is waiting for your valuable report.
[카카오톡] Search YTN to add a channel [전화] 02-398-8585 [메일] [email protected] [온라인 제보] www.ytn.co.kr
